4.6 Article

Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma

期刊

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 48, 期 8, 页码 1167-1170

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/CCLM.2010.219

关键词

gliomas; glioblastoma multiforme; KLF6-SV1; Kruppel-like factor (KLF)6

向作者/读者索取更多资源

Background: Gliomas constitute the vast majority of primary central nervous system tumors in adults. Glioblastoma multiforme (GBM) is the most aggressive form of these primary brain tumors. There is a need to define diagnostic and prognostic markers that may help to distinguish GBM from non-GBM tumors. The Kruppel-like factor 6 (KLF6) gene has recently emerged as a promising candidate. The goal of our study was to determine if there is a link between KLF6 splice variants expression and different grades of gliomas. Methods: Fifty-three primary gliomas tumor samples were analyzed using quantitative real-time PCR for the total KLF6, wild-type and alternatively spliced (SV1) KLF6 mRNA. Results: Compared to the non-GBM group, the GBM group had a 2.2-fold increase in the mean level of total KLF6 mRNA expression. GBM showed a 2.1-fold increase in the KLF6 splicing ratio. In addition, KLF6-SV1 mRNA expression levels were also 2.2-fold higher in the GBM group, suggesting that the increase in the KLF6 splicing ratio was due to increased expression of the KLF6-SV1 oncogenic splice variant. Conclusions: Our study demonstrates that quantification of total and spliced forms of KLF6 may provide a new and useful supplementary molecular tool for grading glioma. Clin Chem Lab Med 2010;48:1167-70.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Relevance of the combination of external beam radiotherapy with the hypoxia-activated prodrug ICF05016 in an experimental model of extraskeletal myxoid chondrosarcoma

Elise Maubert, Valerie Weber, Aurelien Voissiere, Yvain Gerard, Veronique Dedieu, Francoise Degoul, Jean-Michel Chezal, Emmanuel Chautard, Elisabeth Miot-Noirault

Summary: This study demonstrated the potential interest of combining HAP ICF05016 with EBR for the management of EMC. The strategy enhanced EBR efficacy at a lower dose and improved survival without side effects, showing promising results in preclinical studies.

INVESTIGATIONAL NEW DRUGS (2021)

Article Oncology

Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma

J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, B. Chauffert, C. Bourgne, D. Richard, I Molnar, S. Levesque, R. Bellini, F. Kwiatkowski, L. Karayan-Tapon, P. Verrelle, C. Godfraind, X. Durando

Summary: This phase 1 trial aimed to determine the maximum tolerated dose of a p38-MAPK inhibitor, ralimetinib, in combination with radiotherapy and chemotherapy for newly diagnosed GBM patients. The study found that the MTD of ralimetinib was 100 mg/12 h, with the main dose-limiting toxicities being hepatic cytolysis and rash.

RADIOTHERAPY AND ONCOLOGY (2021)

Article Oncology

Hypofractionated stereotactic radiotherapy for large brain metastases: Optimizing the dosimetric parameters

L. Brun, G. Dupic, V Chassin, E. Chautard, J. Moreau, V Dedieu, T. Khalil, P. Verrelle, M. Lapeyre, J. Biau

Summary: The study aimed to compare dosimetric results of four plans for hypofractionated stereotactic radiotherapy (HFSRT) for large brain metastases, finding that NovalisTx (R) VMAT HFSRT provided the best dosimetric compromise for >= 25 mm diameter brain metastases in terms of target coverage, sparing of healthy brain tissue, and low-dose delivery compared to DCA.

CANCER RADIOTHERAPIE (2021)

Article Oncology

Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage

Elisa Le Boiteux, Franck Court, Pierre-Olivier Guichet, Catherine Vaurs-Barriere, Isabelle Vaillant, Emmanuel Chautard, Pierre Verrelle, Bruno M. Costa, Lucie Karayan-Tapon, Anne Fogli, Philippe Arnaud

Summary: HOX gene deregulation may contribute to the development of adult glioma by leading to widespread upregulation of HOX genes, possibly through escape from DNA hypermethylation at CpG island promoters. The study provides a comprehensive description of epigenetic changes at HOX clusters and their contribution to transcriptional changes observed in adult glioma, as well as identifying potential 'master' HOX proteins that may contribute to the tumorigenic potential of glioma stem cells.

MOLECULAR ONCOLOGY (2021)

Review Oncology

Interest and Limits of [18F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy

Elodie Jouberton, Sebastien Schmitt, Aurelie Maisonial-Besset, Emmanuel Chautard, Frederique Penault-Llorca, Florent Cachin

Summary: This article reviews the use of [F-18]ML-10 as a radiotracer for evaluating tumor response to treatment through apoptosis. While most studies suggest its good ability to target apoptotic cells, an increase in apoptosis during treatment did not correlate with the radiotracer tumoral uptake.

FRONTIERS IN ONCOLOGY (2021)

Article Biochemistry & Molecular Biology

L1 chimeric transcripts are expressed in healthy brain and their deregulation in glioma follows that of their host locus

Marie-Elisa Pinson, Franck Court, Aymeric Masson, Yoan Renaud, Allison Fantini, Ophelie Bacoeur-Ouzillou, Marie Barriere, Bruno Pereira, Pierre-Olivier Guichet, Emmanuel Chautard, Lucie Karayan-Tapon, Pierre Verrelle, Philippe Arnaud, Catherine Vaurs-Barriere

Summary: In addition to the consequences of retrotransposition, L1 retrotransposons affect the host genome through their antisense promoter. The study found widespread expression of LCT in normal brain and glioma samples, with the transcriptional activities of L1 antisense promoters and their host loci being coupled.

HUMAN MOLECULAR GENETICS (2022)

Article Biochemistry & Molecular Biology

The Long Non-Coding RNA HOXA-AS2 Promotes Proliferation of Glioma Stem Cells and Modulates Their Inflammation Pathway Mainly through Post-Transcriptional Regulation

Elisa Le Boiteux, Pierre-Olivier Guichet, Konstantin Masliantsev, Bertille Montibus, Catherine Vaurs-Barriere, Celine Gonthier-Gueret, Emmanuel Chautard, Pierre Verrelle, Lucie Karayan-Tapon, Anne Fogli, Franck Court, Philippe Arnaud

Summary: The overexpression of long non-coding RNA HOXA-AS2 in Glioma Stem Cells (GSCs) contributes to their aggressiveness by promoting proliferation and modulating the inflammation pathway through the regulation of key transcription factors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Y. Tao, J. Biau, X. S. Sun, C. Sire, L. Martin, M. Alfonsi, J. B. Prevost, A. Modesto, C. Lafond, J. M. Tourani, J. Miroir, M. C. Kaminsky, A. Coutte, X. Liem, E. Chautard, E. Vauleon, F. Drouet, A. Ruffer, J. F. Ramee, G. Waksi, A. Pechery, M. Wanneveich, J. Guigay, A. Auperin, J. Bourhis

Summary: This study aimed to evaluate the potential synergistic effect of pembrolizumab with radiotherapy compared with a standard-of-care cetuximab-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The results showed that pembrolizumab concomitant with radiotherapy did not improve tumor control and survival compared with cetuximab-radiotherapy, but it appeared to be less toxic in unfit patients with LA-SCCHN.

ANNALS OF ONCOLOGY (2023)

Review Biochemistry & Molecular Biology

Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules

Terrance J. Haanen, Caitlin M. O'Connor, Goutham Narla

Summary: Protein phosphatase 2A (PP2A) is an enzyme that regulates protein phosphorylation and has anti-cancer effects. In cancer, the activity and heterotrimer formation of PP2A are regulated by various mechanisms, which can bias its activity towards oncogenic functions. Therapeutic approaches such as molecular glues and disruptors can be used to treat cancer.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Letter Oncology

The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogenetique Hematologique (GFCH)

Florence Nguyen-Khac, Audrey Bidet, Marie-Berengere Troadec, Lauren Veronese, Nathalie Auger, Agnes Daudignon, Nathalie Nadal, Dominique Penther, Lucienne Michaux, Marina Lafage-Pochitaloff, Christine Lefebvre

LEUKEMIA (2023)

Article Oncology

Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker

Eve Faugeras, Lauren Veronese, Gaelle Jeannin, Henri Janicot, Sebastien Bailly, Jacques-Olivier Bay, Bruno Pereira, Anne Cayre, Frederique Penault-Llorca, Florent Cachin, Patrick Merle, Andrei Tchirkov

Summary: In patients with advanced non-small cell lung cancer (NSCLC), short telomeres, high levels of telomerase, and aberrant expression of shelterin genes TRF2, RAP1, and TIN2 are significantly associated with shorter survival. The determination of telomere parameters in NSCLC could be useful for individualized treatment decisions.

CANCERS (2023)

Article Oncology

Optical Genome Mapping in Routine Cytogenetic Diagnosis of Acute Leukemia

Gwendoline Soler, Zangbewende Guy Ouedraogo, Carole Goumy, Benjamin Lebecque, Gaspar Aspas Requena, Aurelie Ravinet, Justyna Kanold, Lauren Veronese, Andrei Tchirkov

Summary: Acute leukemia is a severe disease with rare occurrences, and genetic characterization plays an important role in its diagnosis and treatment. This study evaluated the performance of optical genome mapping (OGM) as a diagnostic tool for acute leukemia and found that OGM provided accurate genetic descriptions and simplified the workflow. It also detected additional genetic alterations of clinical interest. OGM shows promise as an alternative to current multiple cytogenetic testing in acute leukemia.

CANCERS (2023)

Article Medicine, Research & Experimental

Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogenetique Hematologique (GFCH)

Matthieu Decamp, Emilie Klein, Catherine Godon, Valentin Lestringant, Pauline Roynard, Olivier Theisen, Melanie Jimenez-Pocquet, Catherine Roche-Lestienne, Audrey Bidet, Lauren Veronese

Summary: Myeloproliferative neoplasms and other hematopoietic cancers have an indolent course, and the identification of acquired genetic abnormalities is crucial for patient management and early detection of high-risk patients. Cytogenetic abnormalities also play an important role in the diagnosis, prognosis, and follow-up of these diseases.

CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2023)

Article Medicine, Research & Experimental

Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the Groupe Francophone de Cytogenetique Hematologique (GFCH)

Jean-Baptiste Gaillarda, Elise Chapirob, Agnes Daudignond, Nathalie Nadale, Dominique Pentherf, Jasmine Chauzeixg, Florence Nguyen-Khacb, Lauren Veroneseh, Christine Lefebvrej

Summary: Mature T-cell and natural killer (NK)-cell neoplasms are a highly heterogeneous group of lymphomas with overlapping clinical and genetic features. Advances in molecular techniques have improved our understanding of the genetic alterations involved in these pathologies and provided recommendations for diagnosis.

CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2023)

Meeting Abstract Oncology

Targeting Protein Phosphatase 2A in Combination with PARP inhibitors for the treatment of high-grade serous epithelial ovarian cancer.

Rita A. Avelar, Amy Armstrong, Goutham Narla, Analisa DiFeo

CLINICAL CANCER RESEARCH (2020)

暂无数据